Huaren Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medicines and medical equipment in China and internationally. It offers nephrology products, including peritoneal dialysate, hemofiltration replacement fluid, and hemofiltration basic solution; respiratory products, such as doxofylline, levofloxacin hydrochloride, and composite potassium hydrogen phosphate injections; caffeine citrate injection; and bulk preparations comprising sodium chloride, glucose, glucose and sodium chloride, compound sodium chloride, sodium lactate ringer's, and compound electrolyte injections, as well as sterile water for injection and rinsing liquid products. The company also provides therapeutic infusion, which includes blood volume expander, haemostatic, nervous system, circulatory system, anti-infectives, anti-hepatitis and hepatitis adjuvant drugs, antineoplastic and adjuvant drugs, and glucose metabolism; and rubber stoppers. In addition, it is involved in software development; investment management; and construction. The company was founded in 1998 and is based in Qingdao, China.
